ducovest

UWM:ARCA-ProShares Ultra Russell2000

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 64.49

Change

+0.01 (+0.02)%

Market Cap

USD 0.21B

Volume

0.34M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Russell 2000? Index. The fund invests in equity securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a float-adjusted, market capitalization-weighted index containing approximately 2000 of the smallest companies in the Russell 3000? Index or approximately 8% of the total market capitalization of the Russell 3000? Index, which in turn represents approximately 98% of the investable U.S. equity market. It is non-diversified.

Company Website : www.proshares.com

Currency: USD

Country : USA

Inception Date: 23/01/2007

Primary Benchmark: Russell 2000 TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.18%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Company Name Allocation
LFUS Littelfuse Inc 0.27 %
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SCYB Schwab Strategic Trust 0.00 %

-0.12 (-0.23%)

 N/A

ETFs Containing UWM

JMBS Janus Henderson Mortgage-.. 0.00 % 0.35 %

-0.10 (-0.23%)

 USD 3.75B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.71% 68% D+ 79% B-
Dividend Return 0.52% 15% F 7% C-
Total Return 24.23% 68% D+ 76% C+
Trailing 12 Months  
Capital Gain -13.41% 21% F 24% F
Dividend Return 0.59% 9% A- 7% C-
Total Return -12.82% 21% F 22% F
Trailing 5 Years  
Capital Gain 75.34% 74% C 85% B
Dividend Return 2.32% 40% F 9% A-
Total Return 77.66% 71% C- 82% B
Average Annual (5 Year Horizon)  
Capital Gain 13.75% 82% B 86% B+
Dividend Return 14.01% 82% B 83% B
Total Return 0.26% 21% F 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 30.15% 8% B- 19% F
Risk Adjusted Return 46.45% 61% D- 58% F
Market Capitalization 0.21B 84% B 29% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.